Q3 2024 · 13F-HR
Casdin Capital, LLCholdings as filed
Filed 2024-11-14 · accession 0000919574-24-006736
$1.50B
Reported value
35
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 09062W204 | BLFS | BIOLIFE SOLUTIONS INC | $218.0M | 14.5% | 8,707,165 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $186.6M | 12.4% | 4,114,283 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $148.8M | 9.92% | 3,507,164 | Common | SOLE |
| 34385P108 | LAB | STANDARD BIOTOOLS INC | $137.5M | 9.17% | 71,254,677 | Common | SOLE |
| 803607100 | SRPT | SAREPTA THERAPEUTICS INC | $134.1M | 8.94% | 1,073,500 | Common | SOLE |
| 452327109 | ILMN | ILLUMINA INC | $97.8M | 6.52% | 750,000 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $95.8M | 6.38% | 2,084,841 | Common | SOLE |
| 75943R102 | RLAY | RELAY THERAPEUTICS INC | $65.5M | 4.37% | 9,251,108 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $46.8M | 3.12% | 170,000 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $44.3M | 2.95% | 650,000 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS INC | $41.1M | 2.74% | 2,000,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $30.7M | 2.05% | 700,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $30.2M | 2.01% | 326,378 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $28.8M | 1.92% | 990,000 | Common | SOLE |
| 192005106 | CDXS | CODEXIS INC | $24.9M | 1.66% | 8,100,000 | Common | SOLE |
| 92337F107 | VCYT | VERACYTE INC | $22.7M | 1.51% | 666,308 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $22.0M | 1.47% | 524,616 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $19.3M | 1.29% | 3,995,571 | Common | SOLE |
| 07373V105 | BEAM | BEAM THERAPEUTICS INC | $19.0M | 1.27% | 775,000 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $13.0M | 0.87% | 6,732,971 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $12.4M | 0.83% | 1,150,000 | Common | SOLE |
| 901384107 | TSVT* | 2SEVENTY BIO INC | $9.4M | 0.63% | 2,000,000 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $9.2M | 0.61% | 1,188,349 | Common | SOLE |
| 87164F105 | SNDX | SYNDAX PHARMACEUTICALS INC | $9.1M | 0.61% | 475,000 | Common | SOLE |
| 40131M109 | GH | GUARDANT HEALTH INC | $8.0M | 0.54% | 350,000 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $5.7M | 0.38% | 296,666 | Common | SOLE |
| 15673T100 | IPSC | CENTURY THERAPEUTICS INC | $5.5M | 0.37% | 3,212,316 | Common | SOLE |
| 384747101 | GRAL | GRAIL INC | $4.8M | 0.32% | 350,000 | Common | SOLE |
| 00091E109 | ABSI | ABSCI CORPORATION | $3.7M | 0.25% | 973,260 | Common | SOLE |
| 69404D108 | PACB | PACIFIC BIOSCIENCES CALIF IN | $1.8M | 0.12% | 1,035,859 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $1.4M | 0.09% | 367,175 | Common | SOLE |
| 30223G102 | EXAIEUR | EXSCIENTIA PLC | $1.0M | 0.07% | 213,900 | Common | SOLE |
| 61225M102 | GLUE | MONTE ROSA THERAPEUTICS INC | $455,874 | 0.03% | 86,014 | Common | SOLE |
| 37611X209 | DNA | GINKGO BIOWORKS HOLDINGS INC | $297,418 | 0.02% | 36,493 | Common | SOLE |
| 50107A104 | KRON1USD | KRONOS BIO INC | $123,827 | 0.01% | 123,839 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.